Lonza is increasing its position in the US with a pending acquisition of five CDMO sites from the life-sciences business of Merck KGaA. What sites and capabilities is the company gaining in the deal?
Orphan drug sales are projected to reach a peak of 30% of the global prescription drug market by 2027 and sales of $400 billion by 2032. What products and companies are leading growth?
In what is projected to be one of the largest IPOs in history, the AI giant, Anthropic, has taken the first step in holding an IPO, with AI in bio/pharmaceutical development a key component in its growth strategy.
Sun Pharma’s pending $11.75-billion acquisition of Organon was one of the largest M&A in 2026 and is aligned with its strategy of in part diversifying into innovator drugs, a step taken by other Indian companies.
Why Biopharma’s Biggest Challenge May Not Be Geopolitics
The deeper threat to the biopharmaceutical industry may come not from macro-level disruption, but from structural pressures on the industry’s innovation-driven model and the biotech ecosystem that supports it.
AI & Digital Transformation: Where Does the Bio/Pharma Industry Stand?
How AI and other digital tools are progressing across the bio/pharmaceutical industry is top of mind. Key perspectives on the use and potential of AI and other digital tools were shared at the DCAT Global Summit.
What are key trends for injectable drugs and the related market impact? From switches from IV-administered to subcutaneous drug delivery and increased interest for home and self administration, DCAT Value Chain Insights provides the latest.
A recent KPMG study of CEOs of large companies, including 400 US companies, found that supply-chain cost reduction and AI integration and upskilling are top priorities of CEOs. How are companies addressing these challenges?
Biomanufacturing Growth: Capacity Trends & CDMO Insights & Outlook
What is the outlook for biomanufacturing (drug substance)? How is industry capacity trending, and what is the outlook for outsourcing? A recent study by BioPlan Associates reveals key insights.
PhRMA Raises A Legal Challenge To Most-Favored-Nation Drug Pricing
The Pharmaceutical Research and Manufacturers of America (PhRMA) has filed a legal complaint that challenges the US government’s most-favored-nation drug pricing policy in the GLOBE Model under Medicare Part B.
